{"Title":"Unum Therapeutics","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"53","Founded":"","Address":"","Phone":"(617) 945-5576","Web_address":"http://www.unumrx.com","Market_cup":"$355.4mil","Revenues":"$8.4 mil (last 12 months)","Net_income":"$-25.6 mil (last 12 months)","Symbol":"UMRX","Exchange":"NASDAQ","Shares":"5.8","Price_range":"$12.00 - $12.00","Est_volume":"$69.2 mil","Manager":"Morgan Stanley/ Cowen","CO_managers":"SunTrust Robinson Humphrey/ Wedbush Securities","Exp_to_trade":"3/29/2018","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patientâ€™s immune system to cure cancer. Our proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. Our product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development."}